Wockhardt - Playing safe
January 8, 2008Habil Khorakiwala, Chairman, Wockhardt, like many of the CEOs BT spoke to, is keen to have a new drug on the market in five years.
However, unlike the others, Khorakiwala wouldn’t be terribly heartbroken—disappointed yes, but not shattered—if his efforts came to a naught.
That’s because NCEs account for just a fifth of Wockhardt’s total spend on R&D. Most of the time—and Wockhardt’s money— spent by the 500 scientists at the Wockhardt R&D Centre in Aurangabad is on creating research expertise in niche areas such as ophthalmology, injectibles, novel drug delivery systems, and peptides.
Yet, there’s little doubt that a new drug on the market is more than a gleam in Khorakiwala’s eye.
In addition, he’s got some 10 molecules in the NCE pipeline (most of them at an early stage of development).
That’s probably why Khorakiwala isn’t in a huge rush to license out the molecule for further development. “The valuation has to be right,” he shrugs. “If it isn’t, we would like to go all the way with this molecule.”
— Brian Carvalho